Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xenyhexenic Acid SCHEMBL5158399 | 1.00 | CYP2C19 (0.51) | CYP2C19PTGS2CTSSCTSKFFAR1 | |
| SCHEMBL667322 | 0.90 | CYP2C19 (0.62) | CYP2C19SMN1; SMN2GRIK1GRIK2 | |
| SCHEMBL6751630 | 0.86 | CYP2C19 (0.47) | CYP2C19PTGS2CTSSCTSKPPARG | |
| SCHEMBL7347852 | 0.81 | CYP2C19 (0.56) | CYP2C19PTGS2CTSSCTSKFFAR1 | |
| SCHEMBL11071970 | 0.81 | CYP2C19 (0.56) | CYP2C19SMN1; SMN2 | |
| SCHEMBL5156636 | 0.80 | CYP2C19 (0.80) | CYP2C19PTGS2CTSSCTSKFFAR1 | |
| SCHEMBL28142590 | 0.79 | MAOB (0.50) | CYP2C19PTGS2FFAR1CYP1A2PPARG | |
| SCHEMBL10886677 | 0.78 | CYP2C19 (0.47) | CYP2C19HPGD | |
| SCHEMBL10886683 | 0.78 | CYP2C19 (0.47) | CYP2C19HPGD | |
| Xenbucin SCHEMBL24134 | 0.78 | PTGS2 (0.58) | PTGS2CTSSCTSKSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| JP-60006637-A | — | — | None | — | — | JP | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| EP-1427386-B1 | PRODUCTS FOR PREVENTING PENETRATION INTO THE SKIN | YISSUM RES DEV CO (IL) | 2010-10-20 | — | — | EP | disclosed |
| US-7736630-B2 | Products for preventing penetration into the skin | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2010-06-15 | — | — | US | disclosed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1427386-A4 | PRODUCTS FOR PREVENTING PENETRATION INTO THE SKIN | YISSUM RES DEV CO (IL) | 2006-01-04 | — | — | EP | disclosed |
| US-4562287-A | ANALGESICS | SCHARPER S.P.A. PER L'INDUSTRIA FARMACEUTICA (IT) | 1985-12-31 | — | — | US | disclosed |
| US-4562287-A | ANALGESICS | SCHARPER S.P.A. PER L'INDUSTRIA FARMACEUTICA (IT) | 1985-12-31 | — | — | US | disclosed |
| US-4542233-A | Process for preparing biaryl compounds via coupling of an arylamine with an arene | BIASCHIM S.P.A. (IT) | 1985-09-17 | — | — | US | disclosed |
| US-4542233-A | Process for preparing biaryl compounds via coupling of an arylamine with an arene | BIASCHIM S.P.A. (IT) | 1985-09-17 | — | — | US | disclosed |
| US-4536515-A | Substituted phenylalkenoic acids and esters | MERCK FROSST CANADA, INC. (CA) | 1985-08-20 | — | — | US | disclosed |
| JP-S606637-A | ANTIINFLAMMATORY 2-(4-BIPHENYLYL)-4-HEXENOIC ACID AND DERIVATIVES | SHIYAAFUAA SPA | 1985-01-14 | — | — | JP | disclosed |
| US-4453005-A | Process for preparing substituted phenylalkenoic acids | MERCK FROSST CANADA, INC. (CA) | 1984-06-05 | — | — | US | disclosed |
| EP-0100120-A1 | Improvement in the process for preparing biaryl compounds via coupling of an arylamine with an arene | Nobel Chemicals AB (SE) | 1984-02-08 | — | — | EP | disclosed |
| EP-0100120-A1 | Improvement in the process for preparing biaryl compounds via coupling of an arylamine with an arene | Nobel Chemicals AB (SE) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | CYP2C19 2594/4885PTGS2 1321/4885CTSS 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.